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**Abstract**

Background: The term antidepressant can be misleading in the field of health care. For instance, if the use of antidepressants is compared to the prevalence of major depressive disorder, it may lead to the conclusion that these medications are over prescribed. This is because antidepressants are used in mood and anxiety disorders, but also for the treatment of insomnia, chronic pain, and migraine prophylaxis.

Methods: 38 medications previously denoted as antidepressants were classified on the basis of their primary neurotransmitter target and others, if any, and how they interact with various neuronal elements. These elements could be for example reuptake transporters, receptors, and enzymes. When interacting with receptors, these medications could be acting as agonists, partial agonists, or antagonists.

Results: Classification of these medications, beyond the initial indication for which they were introduced on the market, led to a comprehensive scheme describing their exact pharmacology and helping physicians prescribe the next step when a first treatment or subsequent attempts have been made. Additional features of these medications summarized in an additional level of description provides other beneficial actions (sometimes with indications of specific targets being engaged at different doses), their most frequent side effects, and drug interactions, including warnings of potential deleterious actions.

Conclusions: This new nomenclature of medications used for depression will facilitate their rational site directed prescription and increase compliance by not exposing patients to a medication initially indicated for another psychiatric disorder, thus helping reduce stigma.
